VICTORIA, BC, May 22 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals Corporation , an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines available for patients with less common diseases, announced that effective today, the Company has been added to the NASDAQ Biotechnology Index(R) .
Launched in 1993, the NASDAQ Biotechnology Index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares Nasdaq Biotechnology IndexSM Fund . Securities included in the NASDAQ Biotechnology Index must be listed on the NASDAQ National Market and be classified according to the FTSE(TM) Global Classification System as either biotechnology or pharmaceutical. Additionally, securities in the index must meet minimum requirements for market value, average daily share volume and seasoning as a public company, among other criteria.
About Aspreva Pharmaceuticals
Aspreva is an emerging pharmaceutical company focused on identifying, developing and, upon regulatory approval, commercializing new indications for approved drugs and late stage drug candidates for patients living with less common diseases. Aspreva is listed on the Nasdaq National Market under the trading symbol “ASPV” and on the Toronto Stock Exchange under the trading symbol “ASV”.
For further information, please contact: Sage Baker Executive Director, Corporate & Investor Affairs Aspreva Pharmaceuticals 250-744-2488 ext. 84270 sbaker@aspreva.com
Aspreva Pharmaceuticals
CONTACT: Sage Baker, Executive Director, Corporate & Investor Affairs,Aspreva Pharmaceuticals, (250) 744-2488 ext. 84270, sbaker@aspreva.com